4th Quarter - Report

FRESENIUS MEDICAL CARE NORTH AMERICA for FRESENIUS MEDICAL CARE NORTH AMERICA

Firm
Client
Income
—
Expenses
$1,370,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Emergency preparedness issues and COVID S. 610 Protecting Medicare and American Farmers from Sequester Cuts Act Telehealth policies/CMS Waivers/dialysis centers End State Renal Disease payment policies H.R.1332 - Telehealth Modernization Act Charitable Premium Assistance Transitional Drug Add-on Payment Adjustment (TDAPA) H.R. 4065- Chronic Kidney Disease Improvement in Research and Treatment Act Clinical Labor Cuts in the Physician Fee Schedule Center for Medicare and Medicaid Services CY2022 Physician Fee Schedule CMS Vaccine Mandate S. 4574/ HR 8254- Bringing Enhanced Treatments and Therapies to ESRD Recipients Kidney Care Act

Foreign entity interest: Fresenius Medical Care AG and Co. KGaA is the sole indirect owner of Fresenius Medical Care Holdings, Inc. (dba Fresenius Medical Care North America) and has an interest in the issues lobbied.

LobbyistCovered position, as disclosed
CHRISTOPHER F BUKI —
STACEY FAHRNER —
LAURA KEMPER —
CAMERON LYNCH —
TALEEN MEKHDJAVAKIAN —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 1332 (117th), S. 4574 (117th), H.R. 8254 (117th), S. 610 (117th), H.R. 4065 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.